-transparent.png){kind=logo}
A male patient still surviving 17 years after the diagnosis of chronic myeloid leukaemic (CML) is described. A chromosome analysis of the bone marrow 16 years after the diagnosis revealed 84% Ph1 negative and 16% Ph1 positive cells, all containing the Y chromosome. The disease has been very sensitive to treatment with busulphan but bone marrow hypoplasia has not been induced. It is probable that in some CML patients with such a double cell population the prognosis may be extraordinarily good and that they run a considerable risk of being overtreated due to a pronounced sensitivity to alkylating drugs. Such rare cases should not serve as arguments for aggressive treatment of CML.
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
May 1986,
British journal of haematology,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
December 1980,
Blood,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
June 1979,
Lancet (London, England),
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
August 2001,
British journal of haematology,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
December 1964,
Lancet (London, England),
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
February 1980,
Clinics in haematology,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
January 1989,
Acta haematologica,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
May 1984,
Scandinavian journal of haematology,
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
September 1984,
Lancet (London, England),
L Brandt, and
F Mitelman, and
A Panani, and
H C Lenner
January 1988,
Haematologica,
